5-(4,4-difluoro-piperidin-1-yl)-pyrazine-2-carboxylic acid methyl ester | 1017604-27-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-(4,4-difluoro-piperidin-1-yl)-pyrazine-2-carboxylic acid methyl ester
• 英文别名: 5-(4,4-difluoro-1-piperidinyl)-2pyrazinecarboxylic acid methyl ester；Methyl 5-(4,4-difluoropiperidin-1-yl)pyrazine-2-carboxylate
• CAS: 1017604-27-1
• 化学式: C₁₁H₁₃F₂N₃O₂
• 分子量: 257.24
• InChiKey: PNQWWNYSHRMIRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  55.3
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• Pyrazine-2-carboxamide derivatives
  申请人：Dietz Michel

  公开号：US20080085905A1

  公开（公告）日：2008-04-10

  The present invention relates to compounds of the formula wherein R 1 to R 4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB 2 receptors.

  本发明涉及以下式的化合物 其中R 1 到R 4 如描述和索赔中定义，并且其药学上可接受的盐。这些化合物对于治疗和/或预防与CB 2 受体调节相关的疾病是有用的。
• OXAZOLINE DERIVATIVES
  申请人：Galley Guido

  公开号：US20110112080A1

  公开（公告）日：2011-05-12

  The invention relates to compounds of formula I wherein the definitions of X, R and R 1 are as defined herein. The compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及公式I中的化合物，其中X、R和R1的定义如本文所述。公式I中的化合物对痕量胺相关受体（TAARs）有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、躁郁症、注意力缺陷多动障碍（ADHD）、与压力相关的障碍、精神分裂症等精神障碍、帕金森病等神经疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢性障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病。
• PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP2076499A2

  公开（公告）日：2009-07-08
• OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS.
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2499121B1

  公开（公告）日：2015-10-07
• US7691863B2
  申请人：——

  公开号：US7691863B2

  公开（公告）日：2010-04-06